aTYR PHARMA (ATYR) Free Cash Flow (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Free Cash Flow data on file, last reported at -$12.7 million in Q1 2026.

• Quarterly Free Cash Flow rose 17.93% year-over-year to -$12.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.3 million (up 4.68% YoY) and the FY2025 annual result came in at -$62.1 million, up 10.29% from the prior year.
• Free Cash Flow eased to -$12.7 million in Q1 2026, from -$12.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.8 million in Q1 2023 to a low of -$22.4 million in Q1 2024.
• A 5-year average of -$13.2 million and a median of -$12.7 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow surged 81.93% — and 2024, when it slumped 1119.88%.
• Tracing ATYR's Free Cash Flow over 5 years: stood at -$11.5 million in 2022, then increased by 3.56% to -$11.1 million in 2023, then dropped by 18.76% to -$13.2 million in 2024, then increased by 7.07% to -$12.2 million in 2025, then dropped by 3.5% to -$12.7 million in 2026.
• The last three Free Cash Flow figures came in at -$12.7 million (Q1 2026), -$12.2 million (Q4 2025), and -$20.5 million (Q3 2025), per Business Quant data.